Our vision is to become the leading biopharmaceutical company focused on neurology, with an initial emphasis on the treatment of dementia by addressing multiple forms and aspects of this condition.
Our mission is to build a pipeline of late stage CNS drugs in a capital efficient manner to deliver value to patients and to shareholders.
Axovant is currently developing two novel compounds: intepirdine, a potent 5HT6 receptor antagonist, and nelotanserin, a potent and highly selective inverse agonist of the 5HT2A receptor.
Our near-term focus is to develop intepirdine for the treatment of Alzheimer’s disease and dementia with Lewy bodies.
We are developing our second compound, nelotanserin, for the treatment of the treatment of Lewy body dementia. In early 2016 we initiated two separate Phase 2 studies of nelotanserin.